Breakthrough T1D and Integrated Nanotherapeutics Collaborate to Advance Development of an Immune Tolerizing Therapeutic to Treat Type 1 Diabetes

Rubriques :

VANCOUVER, British Columbia & NEW YORK — Integrated Nanotherapeutics (INT), a biotechnology company developing innovative treatments for autoimmune diseases, has received an award from Breakthrough T1D (formerly JDRF) to advance INT’s technology to induce immune tolerance in type 1 diabetes (T1D). INT’s development of an immune tolerizing therapeutic designed to train the immune system not […]

Breakthrough T1D and Integrated Nanotherapeutics Collaborate to Advance Development of an Immune Tolerizing Therapeutic to Treat Type 1 Diabetes

financialpost.com - 09/Sep 16:02

VANCOUVER, British Columbia & NEW YORK — Integrated Nanotherapeutics (INT), a biotechnology company developing innovative treatments for...

Stealth BioTherapeutics to receive FARA grant to develop investigational mitochondrial therapeutic SBT─589 for Friedreich's ataxia

pharmabiz.com - 13/Sep 16:48

Stealth BioTherapeutics Inc., a clinical─stage biotechnology company focused on the discovery, development and commercialization of novel therapies...

Stealth BioTherapeutics to receive FARA grant to develop investigational mitochondrial therapeutic SBT─589 for Friedreich's ataxia

pharmabiz.com - 13/Sep 16:48

Stealth BioTherapeutics Inc., a clinical─stage biotechnology company focused on the discovery, development and commercialization of novel therapies...

Acepodia inks clinical collaboration with Pfizer to accelerate development of ACC─based cell therapies in autoimmune diseases

pharmabiz.com - 05/Sep 00:00

Acepodia, a clinical─stage biotechnology company developing first─in─class cell therapies with its unique antibody─cell conjugation (ACC) and...

Acepodia inks clinical collaboration with Pfizer to accelerate development of ACC─based cell therapies in autoimmune diseases

pharmabiz.com - 05/Sep 00:00

Acepodia, a clinical─stage biotechnology company developing first─in─class cell therapies with its unique antibody─cell conjugation (ACC) and...

Immune cell ‘atlas’ will help kids fight life-threatening diseases

oncologynews.com.au - 11/Sep 13:59

Researchers at The University of Queensland are developing a comprehensive paediatric immune cell ‘atlas’ to aid in the diagnosis and treatment of...

First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome

drugs.com - 05/Sep 04:09

NEW YORK, Sept. 4, 2024. Immunic, Inc., a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

Rubriques :

Breakthrough T1D and Integrated Nanotherapeutics Collaborate to Advance Development of an Immune Tolerizing Therapeutic to Treat Type 1 Diabetes

Articles similaires

Breakthrough T1D and Integrated Nanotherapeutics Collaborate to Advance Development of an Immune Tolerizing Therapeutic to Treat Type 1 Diabetes

Stealth BioTherapeutics to receive FARA grant to develop investigational mitochondrial therapeutic SBT─589 for Friedreich's ataxia

Stealth BioTherapeutics to receive FARA grant to develop investigational mitochondrial therapeutic SBT─589 for Friedreich's ataxia

Acepodia inks clinical collaboration with Pfizer to accelerate development of ACC─based cell therapies in autoimmune diseases

Acepodia inks clinical collaboration with Pfizer to accelerate development of ACC─based cell therapies in autoimmune diseases

Immune cell ‘atlas’ will help kids fight life-threatening diseases

First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome

Ozempic, Mounjaro Help People With Type 1 Diabetes Control Blood Sugar, Lose Weight

Ozempic, Mounjaro Help People With Type 1 Diabetes Control Blood Sugar, Lose Weight

Fruit and oats raise risk of type 1 diabetes but berries provide protection, research suggests

Les derniers communiqués